Convatec welcomes continued Medicare coverage for InnovaMatrix® in 2026 under Local Coverage Determinations (LCDs) on skin substitutes
London, UK, 16 December 2025 – Convatec welcomes confirmation published on 15 December 2025 by the Centers for Medicare & Medicaid Services (CMS) that InnovaMatrix® will continue to be covered for Medicare patients during 2026 under the LCDs.
We are very pleased that patients and healthcare professionals will continue to have access to InnovaMatrix®, which has generated strong user feedback and clinical evidence. We submitted further real-world evidence (RWE) in October 2025 which has secured InnovaMatrix® coverage with CMS and our randomised controlled trials are on track to publish in 2026.
InnovaMatrix® represented c.3% of Convatec sales in H1 2025. Our guidance for FY25 InnovaMatrix® revenue is unchanged and we continue to expect a headwind to Group revenue of 1-2% in 2026 as a result of the previously announced $127 per sq cm CMS payment rate for skin substitutes. As stated in our 10-month trading update, we expect to deliver double-digit Group adjusted EPS growth in 2026.
Contacts
Analysts & investors: ir@convatec.com
Media: mediarelations@convatec.com
About InnovaMatrix®
InnovaMatrix® is a leading porcine placental-derived extra-cellular matrix for treatment of chronic, surgical and trauma wounds. The product is cleared by the US Food and Drug Administration (FDA) in 15 separate medical indications, based on an established predicate product, under a 510k medical device licence. Patients and HCPs have experienced first-hand the positive impact that InnovaMatrix® products have on chronic wounds, including its potential to prevent amputation. Our randomised controlled trials are on track to publish in 2026.
About Convatec
Pioneering trusted medical solutions to improve the lives we touch: Convatec is a global medical products and technologies company, focused on solutions for the management of chronic conditions, with leading positions in Advanced Wound Care, Ostomy Care, Continence Care, and Infusion Care. With more than 10,000 colleagues, we provide products and services in around 90 countries, united by a promise to be forever caring. Our solutions provide a range of benefits, from infection prevention, treatment for hard to heal wounds, at-risk skin and ulcerated tissue to supporting debilitating conditions, improved patient outcomes and reduced care costs. Convatec's revenues in 2024 were over $2 billion. The company is a constituent of the FTSE 100 Index (LSE:CTEC). To learn more please visit http://www.convatecgroup.com.
Press Release
16-Dec-25
Corporate
Advanced Wound Care
Convatec welcomes continued Medicare coverage for InnovaMatrix® in 2026 under...
Convatec welcomes continued Medicare coverage for InnovaMatrix® in 2026 under final LCDs on skin substitutes
Read more Read more01-Dec-25
Corporate
Continence Care
Ostomy Care
Convatec notes CMS decision on Medicare competitive bidding program in the Un...
CMS released a final rule outlining updates for the CY 2026 Medicare Home Health payment system and the DMEPOS CBP.
Read more Read more13-Nov-25
Corporate
Financial Performance
Trading update for the ten months ended 31 October 2025
Convatec announces its trading update for the ten months ended 31 October 2025.
Read more Read more06-Nov-25
Corporate
Our People
Chief Executive Officer and Chief Financial Officer appointments
The Board of Directors is pleased to announce the appointments of Jonny Mason and Fiona Ryder.
Read more Read more03-Nov-25
Corporate
Advanced Wound Care
Convatec notes CMS payment plans for skin substitutes in the United States
Convatec notes the Centers for Medicare & Medicaid Services (CMS) decision published on 31 October 2025
Read more Read more27-Oct-25
Corporate
Convatec announces Karim Bitar has passed away
Interim leadership arrangements remain in place and a further announcement will be made in due course
Read more Read more27-Oct-25
Corporate
Ostomy Care
Stigma, not condition, is the biggest barrier for 1 in 3 people living with c...
New report reveals that millions of people feel they need to hide their health conditions
Read more Read more08-Oct-25
Corporate
Convatec announces closing of $500 Million 5.300% Senior Notes due 2035
Read more Read more02-Oct-25
Corporate
Convatec announces pricing of $500 Million 5.300% Senior Notes due 2035
Read more Read more01-Oct-25
Corporate
Convatec announces plans to invest more than $1 billion in R&D facilities – ...
Major expansions in the US and UK
Read more Read more22-Sep-25
Corporate
Advanced Wound Care
Convatec secures regulatory approval for ConvaMatrix™ in UK and Europe, suppo...
ConvaMatrix has significant potential for the management of hard to heal wounds such as venous leg ulcers and diabeti...
Read more Read more02-Sep-25
Corporate
Advanced Wound Care
Convatec strengthens Leadership Team to support growth
Read more Read more